Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
|ClinicalTrials.gov Identifier: NCT02551744|
Recruitment Status : Completed
First Posted : September 16, 2015
Results First Posted : August 8, 2019
Last Update Posted : August 8, 2019
|Condition or disease||Intervention/treatment||Phase|
|Peptic Ulcer||Drug: histamine-2 receptor antagonist group Drug: proton pump inhibitor group||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||101 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users — a Double-blind Randomized Controlled Trial|
|Study Start Date :||July 2012|
|Actual Primary Completion Date :||July 2018|
|Actual Study Completion Date :||July 2018|
Active Comparator: proton pump inhibitor group
Pantoprazole Tab 40mg qd for 6 monthrs.
Drug: proton pump inhibitor group
pantoprazole tab 40 mg qd for 6 months.
Other Name: pantoprazole 40mg
Experimental: histamine-2 receptor antagonist group
famotidine Tab 40 mg qd for 6 months.
Drug: histamine-2 receptor antagonist group
famotidine tab 40 mg qd for 6 months.
Other Name: famotidine 40 mg
- Number of Participants With Ulcer Recurrence [ Time Frame: six month ]Follow-up endoscopy was performed at the end of the 6th month
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02551744
|Kaohsiung Veterans General Hospital|
|Kaohsiung, Taiwan, 813|
|Study Chair:||Ping-I Hus, Bachelor||Kaohsiung Veterans General Hospital.|